An Icelandic biotechnology company on Wednesday will begin offering a new genetic test to assess a woman's risk for the most common forms of breast cancer, reigniting concern about the proliferation of unregulated genetic tests, the Washington Post reports. FDA does not regulate screening tests when they are conducted by the labs that offer them.
More...
Linear Mode
